RxDoctor Payments DataLook up a doctor →

Susanne Arnold, MD

Medical Oncology · Lexington, KYNPI 1114934056

Payments from drug & device makers

$5,185,543in general payments, 2019–2025

Across 325 payments — averaging $15,956 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$4.3M
  • AbbVie$287K
  • AstraZeneca$123K
  • Amgen$103K
  • Exelixis Inc.$87K
  • Eli Lilly$62K
  • plus $257K from 13 others

What the payments were for

  • Education$99100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,185,543 in reported general payments places this provider in the 95th percentile of 53 medical oncology providers in Kentucky.

See all medical oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$56,481
Medicare patients
178
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate21$309,218
EliquisApixaban30$24,956
Oxycodone Hcl252$15,875
Ondansetron Hcl98$9,810
Fentanyl48$4,541
Gabapentin107$3,826
Levothyroxine Sodium287$2,897
Ondansetron OdtOndansetron66$1,926
Prochlorperazine Maleate109$1,411
Dexamethasone60$1,227
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$1,115
ValacyclovirValacyclovir Hcl13$959
Ventolin HfaAlbuterol Sulfate16$924
Megestrol Acetate11$899
Famotidine22$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$122,544$309,21821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 medical oncology providers in Kentucky.

Other medical oncology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →